Hormonal
SIRT1 activation via resveratrol or genetic overexpression can extend healthspan and protect skeletal muscle from catabolic stress (e.g., TNF-alpha, disuse), but its effect on basal muscle mass and differentiation is complex and potentially inhibitory.
SIRT1 activators like resveratrol are popular for longevity, but their effect on muscle is nuanced. They may help protect muscle during illness, injury, or disuse by reducing inflammation and oxidative stress. However, they might also inhibit muscle growth and differentiation in healthy, well-fed individuals. Therefore, using SIRT1 activators for muscle building is not supported, but they might have a role in maintaining muscle during periods of stress or aging.
activation of SIRT1 in murine myoblasts following resveratrol administration can begin to rescue differentiation of SkM cells following catabolic stimulation by TNF-a... increasing SIRT1 activity in mouse and human SkM cells impaired differentiation and myosin heavy chain production
Why this rating
Evidence is mixed, with some studies showing benefit under stress and others showing impairment of differentiation under normal conditions.
Source
Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake
Adam P. Sharples et al. · Aging Cell · 2015
DOI 10.1111/acel.12342
More from this paper
- Reduced insulin/insulin-like growth factor (IIS) signaling extends lifespan and healthspan in model organisms but is associated with reduced skeletal muscle mass and function in aging humans.Good
- Dietary restriction (DR) extends lifespan and healthspan in model organisms, but its impact on skeletal muscle mass is complex, potentially attenuating age-related loss in some species while causing absolute mass decrease in others.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →